Merrion Pharm Plc (IRSH) - Novo Nordisk Trial Result
RNS Number : 8550P
Merrion Pharmaceuticals Public Ltd
31 October 2012
Novo Nordisk A/S Successfully Completes Single Dose Phase 1 Trial of Oral
GLP-1 Analogue (NN9926) Using Merrion Pharmaceuticals GIPET Technology.
Merrion Pharmaceuticals plc (ESM:MERR), today announces that its partner, Novo
Nordisk, successfully completed a Phase I trial with an oral formulation of a
Novo Nordisk proprietary GLP-1 analogue. Merrion's proprietary GIPET
Technology was incorporated in the formulation in order to enhance the oral
bioavailability of the drug.
The aim of the trial was to investigate the safety, tolerance and
pharmacokinetics, of the GLP-1 analogue NN9926.
Under the terms of the license agreement signed in January 2009, Merrion will
receive payments for products developed under the agreement. Payments are
based on achievement of certain development, regulatory and sales milestones
as well as royalties. Certain milestone payments have been received by
Merrion as a result of this successful Phase 1 trial.
Merrion's Chairman, Michael Donnelly said "We are very pleased with this
outcome and the commitment of Novo Nordisk to the continuing development of
Merrion's GIPET technology in this field".
This information is provided by RNS
The company news service from the London Stock Exchange
MSCBKKDDBBDDOKN -0- Oct/31/2012 09:00 GMT
Press spacebar to pause and continue. Press esc to stop.